10-Q: Precipio Inc. Reports Increased Revenue in Q1 2025, but Going Concern Uncertainty Remains

Precipio Inc. saw a significant revenue increase in the first quarter of 2025, but faces ongoing concerns about its ability to continue as a going concern.

Summary

• Precipio Inc. reported net sales of $4.929 million for the three months ended March 31, 2025, compared to $3.432 million for the same period in 2024.
• Service revenue, net, increased by $1.5 million to $4.275 million, driven by a 47% increase in cases processed.
• The company's gross profit was $2.140 million, with a gross margin of 43%, compared to $0.920 million and 27% in the prior year period.
• Operating expenses remained relatively flat at $2.999 million.
• The net loss for the quarter was $0.884 million, compared to $2.079 million in the first quarter of 2024.
• Basic and diluted loss per common share was $(0.59), compared to $(1.46) in the prior year period.
• The company had a working capital deficit of $1.1 million as of March 31, 2025.
• There remains substantial doubt about the company's ability to continue as a going concern.
• The company is pursuing additional financing through an existing sales agreement with AGP, with approximately $3.7 million available for future sales.
• Precipio received an initial payment of approximately $0.4 million from an Employee Retention Credit (ERC) claim and anticipates recording this amount as other income in the second quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents mixed signals. Revenue is up and losses are down, which is positive. However, the going concern warning and working capital deficit are significant negatives. The sentiment is neutral, leaning slightly negative.

Positives

• Significant increase in net sales and service revenue.
• Improved gross margin compared to the prior year period.
• Reduced net loss compared to the prior year period.
• Receipt of $0.4 million from an Employee Retention Credit (ERC) claim.
• The company is actively pursuing additional financing through a sales agreement with AGP, with $3.7 million available for future sales.

Negatives

• The company has a working capital deficit of $1.1 million as of March 31, 2025.
• There remains substantial doubt about the company's ability to continue as a going concern.
• The company wrote off $0.1 million related to the Change Healthcare (CHC) temporary funding assistance program.

Risks

• The company's ability to continue as a going concern is dependent on generating additional revenue and raising additional financing.
• The company has incurred substantial operating losses and has used cash in its operating activities for the past several years.
• The healthcare industry is subject to numerous laws and regulations, and violations could result in significant penalties.
• The outcome of legal proceedings and claims brought against the company are subject to significant uncertainty.
• The company's reliance on Change Healthcare (CHC) for billing services was disrupted by a cybersecurity breach, causing billing and cash reimbursement delays.

Future Outlook

The company's future performance is dependent on achieving its business plan, generating additional revenue, and raising additional financing to meet its debt obligations and pay liabilities.

Industry Context

The healthcare industry is subject to numerous laws and regulations, including those related to licensure, accreditation, government healthcare program participation, and fraud and abuse.

Legal Proceedings

• The Company is currently involved in a legal proceeding brought by a former employee before the court in San Antonio, Texas alleging unfair dismissal where the former employee seeks monetary damages.

Stakeholder Impact

• The company's ability to continue as a going concern impacts shareholders, employees, customers, and suppliers.

Next Steps

• The company will make equal monthly payments of approximately $83,000 from May 2025 to January 2026 to settle the balance owed to CHC.
• The Company anticipates recording the $0.4 million ERC payment as other income in the condensed consolidated statements of operations for the second quarter 2025.
• The Company will make equal monthly payments of approximately $83,000 from May 2025 to January 2026 to settle the balance owed to CHC.

Key Dates

Keywords

diagnostics, cancer, revenue, financial results, going concern, Precipio, sales, AGP, ERC, CLIA